Possessing Next-Generation Technologies Such as AI Antibodies and Organoids

Providing Tailored Support for Technology Advancement and Collaboration Opportunities

On June 10, Celltrion announced that it has finalized the selection of four companies to participate in the 4th class of the '2026 Seoul Bio Hub-Celltrion Open Innovation Program' and will work to enhance its collaboration system with promising bio and medical startups.


Participants are taking a commemorative photo at the orientation (OT) of the 4th term of the '2026 Seoul Biohub-Celtrion Open Innovation Program' held by Celtrion on the 10th at the Celtrion Global Biotech Research Center in Songdo, Incheon. Celtrion

Participants are taking a commemorative photo at the orientation (OT) of the 4th term of the '2026 Seoul Biohub-Celtrion Open Innovation Program' held by Celtrion on the 10th at the Celtrion Global Biotech Research Center in Songdo, Incheon. Celtrion

View original image

The four companies selected for the 4th class are: ▲AINB, which offers an AI-driven protein antibody development platform; ▲NbioCell, which provides an oral delivery formulation platform for GLP-1 derivatives based on ChargeSmed™; ▲IMITA Science, which specializes in disease modeling and drug evaluation technologies based on biomimetic tissue; and ▲Podotherapeutics, which provides a precision medicine platform based on patient-derived organoids (PDO).


This program was established to discover bio and medical startups that possess innovative technologies applicable to Celltrion’s research and development needs. In cooperation with Seoul Bio Hub, it aims to support the advancement of these technologies and broaden the foundation for growth. Candidate companies were selected through an evaluation process involving external technology assessment experts. The selected companies will receive tailored support at each stage of growth, including joint research and commercialization opportunity reviews with Celltrion, technology advancement support, and mentoring.


The agreement ceremony was held on the same day at Celltrion's Global Biotech Research Center in Songdo, Incheon. Representatives from Celltrion, the Seoul Metropolitan Government, Seoul Bio Hub, and the selected companies attended. The event included a welcome speech, introduction of the selected companies and the program, signing of the program agreement, a commemorative photo session, and a tour of the research center.


Celltrion has already achieved significant results through previous open innovation programs. The 1st class company, EnteroBiome, became the first Korean firm to win the 2024 KLSAP and successfully secured investments worth around 10 billion won through the global bio cluster competition program provided by Celltrion. The 2nd class company, Biomee, is accelerating new drug development through a joint research and equity investment agreement with Celltrion. The 3rd class companies, MustBio, Galux, and Portrait, have also signed joint research agreements with Celltrion.


A Celltrion official stated, "The 4th class companies possess differentiated and highly applicable technologies, including AI-based protein antibody development, oral delivery of GLP-1 derivatives, disease modeling, and organoid-based precision medicine. We will continue to expand collaboration opportunities with promising startups and strive to contribute to the sustainable growth of the domestic bio ecosystem."



Meanwhile, since 2020, Celltrion has participated as a private operator in the Incheon Startup Park development project and continues its open innovation activities to discover and nurture promising bio companies, including its involvement in the K-Bio Lab Hub establishment project.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing